Drug Information
Drug (ID: DG01488) and It's Reported Resistant Information
| Name |
N-arachidonoyl dopamine
|
||||
|---|---|---|---|---|---|
| Synonyms |
NADA; N-Arachidonoyl dopamine; Arachidonoyl dopamine; 199875-69-9; N-Arachidonyldopamine; N-Arachidonyl dopamine; Arachidonyl dopamine; N-arachidonoyldopamine; (5Z,8Z,11Z,14Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide; CHEMBL138921; CHEBI:31231; N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-dopamine; N-[2-(3,4-Dihydroxyphenyl)ethyl]-5Z,8Z,11Z,14Z-eicosatetraenamide; NADA dopamine; 5,8,11,14-Eicosatetraenamide, N-[2-(3,4-dihydroxyphenyl)ethyl]-,(5Z,8Z,11Z,14Z)-; AA-DA; n-arachidonoyl-dopamine; SCHEMBL154051; BML3-G03; GTPL4261; N-arachidonoyl-dopamine (NADA); BDBM20462; DTXSID70415208; HMS3649B19; ZINC4102443; 1907AH; LMFA08020084; AKOS015951332; NCGC00161231-03; NCGC00161231-04; NCGC00161231-05; HY-110018; SR-01000946639; Q3869319; SR-01000946639-1; Arachidonoyl dopamine, >=98% (HPLC), ethanol solution
Click to Show/Hide
|
||||
| Indication |
In total 1 Indication(s)
|
||||
| Structure |
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
| Formula |
17
|
||||
| IsoSMILES |
CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCC1=CC(=C(C=C1)O)O
|
||||
| InChI |
InChI=1S/C28H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-28(32)29-23-22-25-20-21-26(30)27(31)24-25/h6-7,9-10,12-13,15-16,20-21,24,30-31H,2-5,8,11,14,17-19,22-23H2,1H3,(H,29,32)/b7-6-,10-9-,13-12-,16-15-
|
||||
| InChIKey |
MVVPIAAVGAWJNQ-DOFZRALJSA-N
|
||||
| PubChem CID | |||||
| ChEBI ID | |||||
| TTD Drug ID | |||||
Type(s) of Resistant Mechanism of This Drug
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | |||||||||||||
|
|
|||||||||||||
| Key Molecule: GTPase Nras (NRAS) | [1] | ||||||||||||
| Sensitive Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | ||||||||||||
| Molecule Alteration | Missense mutation | p.G12D (c.35G>A) |
|||||||||||
| Wild Type Structure | Method: X-ray diffraction | Resolution: 1.40 Å | |||||||||||
| Mutant Type Structure | Method: X-ray diffraction | Resolution: 2.10 Å | |||||||||||
| Download The Information of Sequence | Download The Structure File | ||||||||||||
-
0
|
G
-
M
M
T
T
E
E
Y
Y
K
K
L
L
V
V
V
V
V
V
10
|
G
G
A
A
G
D
G
G
V
V
G
G
K
K
S
S
A
A
L
L
20
|
T
T
I
I
Q
Q
L
L
I
I
Q
Q
N
N
H
H
F
F
V
V
30
|
D
D
E
E
Y
Y
D
D
P
P
T
T
I
I
E
E
D
D
S
S
40
|
Y
Y
R
R
K
K
Q
Q
V
V
V
V
I
I
D
D
G
G
E
E
50
|
T
T
C
C
L
L
L
L
D
D
I
I
L
L
D
D
T
T
A
A
60
|
G
G
Q
Q
E
E
E
E
Y
Y
S
S
A
A
M
M
R
R
D
D
70
|
Q
Q
Y
Y
M
M
R
R
T
T
G
G
E
E
G
G
F
F
L
L
80
|
C
C
V
V
F
F
A
A
I
I
N
N
N
N
T
T
K
K
S
S
90
|
F
F
E
E
D
D
I
I
H
H
H
H
Y
Y
R
R
E
E
Q
Q
100
|
I
I
K
K
R
R
V
V
K
K
D
D
S
S
E
E
D
D
V
V
110
|
P
P
M
M
V
V
L
L
V
V
G
G
N
N
K
K
C
C
D
D
120
|
L
L
P
P
S
S
R
R
T
T
V
V
D
D
T
T
K
K
Q
Q
130
|
A
A
Q
Q
D
D
L
L
A
A
R
R
S
S
Y
Y
G
G
I
I
140
|
P
P
F
F
I
I
E
E
T
T
S
S
A
A
K
K
T
T
R
R
150
|
Q
Q
G
R
V
V
D
E
D
D
A
A
F
F
Y
Y
T
T
L
L
160
|
V
V
R
R
E
E
I
I
R
R
K
Q
H
Y
K
R
E
L
K
K
|
|||||||||||||
| Experimental Note | Revealed Based on the Cell Line Data | ||||||||||||
| In Vitro Model | Ba/F3 cells | Colon | Homo sapiens (Human) | CVCL_0161 | |||||||||
| NIH3T3 cells | Embryo | Homo sapiens (Human) | CVCL_0594 | ||||||||||
| WEHI-3 cells | Peripheral blood | Mus musculus (Mouse) | CVCL_3622 | ||||||||||
| Bosc23 cells | Fetal kidney | Homo sapiens (Human) | CVCL_4401 | ||||||||||
| Experiment for Molecule Alteration |
Western blot analysis | ||||||||||||
| Experiment for Drug Resistance |
Promega assay | ||||||||||||
| Mechanism Description | N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation. | ||||||||||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.
